首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem.
【24h】

Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem.

机译:仲烷基胺向代谢中间复合物的顺序代谢:地昔帕明,(s)-氟西汀和N-去甲基地尔硫ze的仲羟胺和伯胺代谢物的相反作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Three secondary amines desipramine (DES), (S)-fluoxetine [(S)-FLX], and N-desmethyldiltiazem (MA) undergo N-hydroxylation to the corresponding secondary hydroxylamines [N-hydroxydesipramine, (S)-N-hydroxyfluoxetine, and N-hydroxy-N-desmethyldiltiazem] by cytochromes P450 2C11, 2C19, and 3A4, respectively. The expected primary amine products, N-desmethyldesipramine, (S)-norfluoxetine, and N,N-didesmethyldiltiazem, are also observed. The formation of metabolic-intermediate (MI) complexes from these substrates and metabolites was examined. In each example, the initial rates of MI complex accumulation followed the order secondary hydroxylamine > secondary amine primary amine, suggesting that the primary amine metabolites do not contribute to formation of MI complexes from these secondary amines. Furthermore, the primary amine metabolites, which accumulate in incubations of the secondary amines, inhibit MI complex formation. Mass balance studies provided estimates of the product ratios of N-dealkylation to N-hydroxylation. The ratios were 2.9 (DES-CYP2C11), 3.6 [(S)-FLX-CYP2C19], and 0.8 (MA-CYP3A4), indicating that secondary hydroxylamines are significant metabolites of the P450-mediated metabolism of secondary alkyl amines. Parallel studies with N-methyl-d(3)-desipramine and CYP2C11 demonstrated significant isotopically sensitive switching from N-demethylation to N-hydroxylation. These findings demonstrate that the major pathway to MI complex formation from these secondary amines arises from N-hydroxylation rather than N-dealkylation and that the primary amines are significant competitive inhibitors of MI complex formation.
机译:三种仲胺desipramine(DES),(S)-氟西汀[(S)-FLX]和N-desmethyldiltiazem(MA)经过N-羟基化反应生成相应的仲羟胺[N-hydroxydesipramine,(S)-N-hydroxyfluoxetine,和N-羟基-N-去甲基去甲乙酰胺]分别由细胞色素P450 2C11、2C19和3A4组成。还观察到了预期的伯胺产物,N-去甲基desipramine,(S)-去氟西汀和N,N-二甲基去甲西ze。检查了由这些底物和代谢产物形成的代谢中间体(MI)复合物。在每个实施例中,MI复合物积累的初始速率遵循仲羟胺>仲胺>伯胺的顺序,这表明伯胺代谢物无助于由这些仲胺形成MI络合物。此外,在仲胺的培养中积累的伯胺代谢物抑制MI复合物的形成。质量平衡研究提供了对N-脱烷基化与N-羟基化的产物比率的估计。比率为2.9(DES-CYP2C11),3.6 [(S)-FLX-CYP2C19]和0.8(MA-CYP3A4),表明仲羟胺是P450介导的仲烷基胺代谢的重要代谢产物。与N-甲基-d(3)-地昔帕明和CYP2C11的并行研究表明,从N-去甲基化到N-羟基化具有明显的同位素敏感性转换。这些发现表明由这些仲胺形成MI复合物的主要途径是由N-羟基化而不是N-脱烷基化引起的,并且伯胺是MI复合物形成的重要竞争性抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号